Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in lymphoma
- Trial result
Lymphoma
Ultrasensitive ctDNA-MRD outperforms PET for defining remission in frontline LBCL
Led by NCI in collaboration with Stanford (developers of PhasED-Seq) and Foresight Diagnostics (CLARITY MRD assay), ultrasensitive ctDNA minimal residual disease (MRD) testing using phased-variant detection (e.g.,…
NCT04002947 - New trial
Lymphoma
Phase II trial: Epcoritamab bispecific antibody (CD20/CD3) plus EPOCH-R in aggressive B-cell NHL.
University of Washington is conducting a Phase II study to evaluate the safety, tolerability, and efficacy of epcoritamab—with its CD20/CD3 targeting mechanism—combined with standard EPOCH-R chemotherapy. The study…
NCT07097363 Exploratory - New trial
Lymphoma
Phase 1 trial of TLN-121, a talin-1 targeted integrin β1 adhesion inhibitor
This open-label, multicenter study sponsored by Treeline Biosciences, Inc. evaluates the safety, pharmacokinetics, and preliminary anti-tumor activity of TLN-121 alone or combined with TLN-254, a BCL6 degrader small…
NCT07082803 First-in-human - New trial
Lymphoma
Phase I/II trial of AZD4512, a CD22‐directed antibody-drug conjugate.
This global open-label study evaluates the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of AZD4512 administered as monotherapy dose escalation (with backfill cohorts) or in combination…
NCT07123454 First-in-human - Trial result
Lymphoma
Acalabrutinib+Lenalidomide+Rituximab (BTK+IMiD+CD20) Hits 92% CR in Frontline High-Burden FL
Acalabrutinib (BTK inhibitor) plus lenalidomide (IMiD) and rituximab (anti-CD20) was tested first-line in a single-arm phase II for advanced-stage follicular lymphoma with high tumor burden (n=24; NCT04404088; median…
NCT04404088 - Trial result
Lymphoma
Obinutuzumab (CD20) Induction+Maintenance Delivers 65% ORR in Relapsed Waldenström’s
Single-arm phase II (NCT03679455) tested obinutuzumab 1000 mg monotherapy (induction then q8wk maintenance ×2 yrs) in relapsed/refractory Waldenström macroglobulinaemia (n=23; median follow-up 3.8 yrs). Best overall…
NCT03679455 - Trial result
Lymphoma
NKTR-255 (IL-15R agonist) Lifts 6-mo CR After CD19 CAR-T in R/R LBCL
Phase 2, randomized, double-blind, placebo-controlled multicenter study (NCT05664217) tested NKTR-255—an IL-15 receptor agonist designed to expand CD8 T and NK cells—given after axi-cel or liso-cel in…
NCT05664217 - Trial result
Lymphoma
Evorpacept (CD47) + Lenalidomide/Rituximab Achieves 80% CR in R/R B-NHL (Phase I)
Evorpacept (ALX148) is a high-affinity CD47 blocker with an inactive Fc to promote macrophage phagocytosis while limiting cytopenias; added to lenalidomide and rituximab (R2) in a single-arm Phase I (n=20; ≥2 prior…
NCT05025800 - New trial
Lymphoma
Phase Ib Trial: Epcoritamab CD20/CD3 bispecific antibody for CNS lymphoma
This trial at Memorial Sloan Kettering evaluates the safety of epcoritamab, CD20/CD3 bispecific antibody, in combination with ibrutinib, a BTK inhibitor, in patients with relapsed/refractory primary or secondary…
NCT07082868 Exploratory - New trial
Lymphoma
Phase 1 ZE50-0134 Investigational BCL‑2 Inhibitor in Relapsed Lymphoid Malignancies
This trial by Eilean Therapeutics evaluates ZE50-0134, a novel BCL‑2 inhibitor, for safety, pharmacokinetics, and preliminary efficacy in patients with relapsed and refractory chronic lymphocytic leukemia, small…
NCT06708897 First-in-human - New trial
Lymphoma
Phase 1 study of CBX-250, an investigational Cathepsin G Peptide-HLA-Targeting T Cell Engager
This Phase 1 open-label dose-escalation trial at Crossbow Therapeutics evaluates the safety and preliminary activity of subcutaneous CBX-250 given in 28-day cycles (with an initial priming phase) in patients aged 12…
NCT06994676 First-in-human - Trial result Spotlight
Lymphoma
Finite‑Course Venetoclax (BCL‑2) Delivers 36 mo Median PFS in Relapsed Waldenström Macroglobulinemia
Venetoclax, an oral BCL‑2 inhibitor, was given at 200→800 mg daily for up to 2 years in a single‑arm phase 2 trial (NCT02677324) of 32 previously treated WM patients (median follow‑up 81 mo). Median progression‑free…
NCT02677324 - Trial result
Lymphoma
Ibrutinib + Rituximab (BTK / CD20) Lifts 48‑mo PFS to 72% in CXCR4‑Mutant Waldenström Macroglobulinemia
Ibrutinib, a covalent BTK inhibitor, plus rituximab (anti-CD20) was compared with ibrutinib alone in a pooled patient‑level analysis of three prospective studies (N=174 MYD88‑mutated WM; 58 I+R, 116 I). Overall VGPR…
- Trial result Spotlight
Lymphoma
Calibrated CD19‑1XX CAR T Achieves 75% CR with Only 4% Grade ≥3 CRS in r/r LBCL
19(T2)28z‑1XX, a CD19 CAR T cell engineered for “just‑right” 1XX signaling, was evaluated in the first‑in‑human phase I dose‑escalation/expansion study NCT04464200. Twenty‑eight adults with relapsed/refractory large…
NCT04464200 - New trial
Lymphoma
Phase 1b Trial of NT-I7, a long-acting IL-7 cytokine boosting T-cell expansion
This Phase 1b study at Washington University School of Medicine evaluates NT-I7—an investigational long-acting human IL-7 cytokine designed to enhance T-cell proliferation—administered intramuscularly on Days 10 and…
NCT07052305 Exploratory - New trial
Lymphoma
Phase II Venetoclax BCL-2 inhibitor trial for relapsed/refractory B-cell lymphomas.
National Cancer Institute is evaluating the ViPOR regimen in patients with relapsed or refractory CD10-negative diffuse large B-cell lymphoma and high-grade B-cell lymphoma with MYC and BCL2 rearrangements. The trial…
NCT06649812 Exploratory - New trial
Lymphoma
Phase 1b Epcoritamab bispecific antibody (CD20/CD4) trial in relapsed/refractory DLBCL
This study from Memorial Sloan Kettering evaluates the safety and efficacy of a three-drug regimen for relapsed or refractory diffuse large B-cell lymphoma. Patients receive subcutaneous epcoritamab (a bispecific…
NCT07030699 Exploratory - Trial result
Lymphoma
Brentuximab Vedotin + Pembrolizumab Yields 88% Pre-ASCT CMR in R/R cHL
Brentuximab vedotin (BV), a CD30-directed ADC, plus the PD-1 inhibitor pembrolizumab was retrospectively used as salvage in 24 heavily pre-treated relapsed/refractory classical Hodgkin lymphoma patients prior to…
- New trial
Lymphoma
Phase I CCR4 CAR T Cells gene therapy targeting CCR4 in T-cell lymphomas
This Phase I trial by the National Cancer Institute tests the safety of administering autologous T cells engineered with an anti-CCR4 CAR. Eligible adults have CCR4+ peripheral or cutaneous T-cell lymphomas that are…
NCT07055477 First-in-human - New trial
Lymphoma
Phase I N-803 study of IL-15 agonist fusion protein in post-CAR T therapy
This Phase I trial seeks to determine the safety and tolerability of N-803, an IL-15 agonist fusion protein, administered as maintenance therapy following CD19-targeted CAR T-cell treatment for patients with relapsed…
NCT07049432 Exploratory - New trial
Lymphoma
Phase I/IB Ropeginterferon Trial Targeting Interferon A2b Protein in CTCL
This single-center study at H. Lee Moffitt Cancer Center is evaluating Ropeginterferon-alfa 2b, administered subcutaneously every 2 weeks at doses from 250 µg to 500 µg, to determine the recommended phase II dose in…
NCT07047885 Exploratory - New trial
Lymphoma
Phase II trial of axicabtagene ciloleucel, a CD19-targeted CAR T cell therapy
This randomized trial led by City of Hope Medical Center evaluates whether fecal microbiome transplantation (FMT) administered before and after standard leukapheresis, chemotherapy, and axicabtagene ciloleucel…
NCT07042438 Exploratory - New trial
Lymphoma
Phase 1b trial: Tazemetostat EZH2 inhibitor with Zanubrutinib BTK inhibitor in indolent NHL.
This trial led by University of Utah evaluates the safety and preliminary efficacy of Tazemetostat (an EZH2 inhibitor) in combination with Zanubrutinib (a BTK inhibitor) and anti-CD20 monoclonal antibodies (rituximab…
NCT06824701 Exploratory - New trial
Lymphoma
Phase 2 pembrolizumab PD-1 inhibitor with GVD consolidation in relapsed/refractory Hodgkin lymphoma
This Phase 2, open-label study evaluates pembrolizumab plus GVD consolidation in relapsed or refractory classic Hodgkin lymphoma patients with prior doxorubicin use. FDG-PET/CT imaging and Foresight CLARITY liquid…
NCT07021989 Exploratory - New trial
Lymphoma
Phase 2 Brentuximab Vedotin ADC, a CD30-targeted tubulin inhibitor.
This trial at the University of Miami evaluates the efficacy and safety of the abbreviated BrECADD regimen in patients with Stage 2B-4 Hodgkin Lymphoma. An exploratory objective is to assess circulating tumor DNA as…
NCT07002216 Exploratory - New trial
Lymphoma
Phase 1b glofitamab CD20/CD3 bispecific mAb for frontline DLBCL in older adults
This study evaluates a combination treatment using glofitamab with polatuzumab, obinutuzumab, and R-miniCHP for untreated patients (65+) with DLBCL, HGBCL, or transformed lymphoma. A response-adapted design based on…
NCT06765317 Exploratory - New trial
Lymphoma
Phase Ib Loncastuximab Tesirine (anti-CD19 ADC) and Roflumilast (PDE4 inhibitor) in High-Risk DLBCL
This Phase Ib single-arm trial evaluates a combination of Loncastuximab Tesirine, Roflumilast, and standard R-CHOP in newly diagnosed high-risk diffuse large B-cell lymphoma. The study, led by The University of Texas…
NCT06977711 Exploratory - New trial
Lymphoma
Phase I alectinib (ALK kinase inhibitor) plus duvelisib (PI3K delta-gamma inhibitor) dual-target trial
This study evaluates the safety and efficacy of alectinib lead-in followed by duvelisib combination to establish tolerable doses in relapsed/refractory ALK+ anaplastic large cell lymphoma. Conducted by Memorial Sloan…
NCT07001384 Exploratory - New trial
Lymphoma
Phase 2 Nivolumab Checkpoint Blockade in Relapsed/Refractory ALK+ ALCL
This trial evaluates risk-adapted chemommunotherapy—with Nivolumab and tailored chemotherapy potentially followed by an allogeneic stem cell transplant—in children, adolescents, and young adults with…
NCT07013565 Exploratory - Trial result
Lymphoma
Obinutuzumab + Lenalidomide Delivers 93% 2-Year PFS in First-Line High-Tumor-Burden FL
Obinutuzumab, a type II anti-CD20 antibody with enhanced ADCC, paired with the IMiD lenalidomide (G-Len) was tested in a single-center phase 2 trial (NCT02871219) in 90 untreated grade 1-3a, stage II–IV…
NCT02871219
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.